World Journal of Urology

, Volume 27, Issue 3, pp 325–330

Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer

Topic Paper


Electromotive drug administration® (EMDA) increases the local drug efficacy by controlling and enhancing transmembranous transport into tissue. EMDA of intravesical mitomycin-C (MMC) has been used for treatment of non-muscle invasive bladder cancer (NMIBC) for about a decade on the basis of laboratory studies that demonstrated an enhanced administration rate of MMC into all bladder wall layers after EMDA compared to standard instillation/passive diffusion (PD). Higher MMC concentrations might have a clinical impact since EMDA was associated with lower recurrence rates than PD in randomized studies. Further data suggest that EMDA/MMC is at least equivalent to BCG in treatment of high-risk bladder tumours. In addition, BCG combined with EMDA/MMC as well as preoperative EMDA/MMC are new therapeutic strategies with promising preliminary results in terms of higher remission rates and longer remission times. In summary, these findings suggest that EMDA for MMC delivery in the bladder could be a major therapeutic breakthrough in the treatment of NMIBC.


Non-muscle invasive bladder cancer Intravesical therapy Electromotive drug administration Mitomycin-C 


  1. 1.
    Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol 26:1–9Google Scholar
  2. 2.
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54:303–314. doi:10.1016/j.eururo.2008.04.051 PubMedCrossRefGoogle Scholar
  3. 3.
    Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, Bijnens L (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156:1934–1940. doi:10.1016/S0022-5347(01)65396-5 PubMedCrossRefGoogle Scholar
  4. 4.
    Lamm DL, Riggs DR, Traynelis CL, Nseyo UO (1995) Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153:1444–1450. doi:10.1016/S0022-5347(01)67427-5 PubMedCrossRefGoogle Scholar
  5. 5.
    Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171:2186–2190. doi:10.1097/01.ju.0000125486.92260.b2 PubMedCrossRefGoogle Scholar
  6. 6.
    Böhle A, Jocham D, Bock PR (2003) Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90–95. doi:10.1016/S0022-5347(05)64043-8 PubMedCrossRefGoogle Scholar
  7. 7.
    Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL-S (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51:5144–5152PubMedGoogle Scholar
  8. 8.
    Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL-S (1991) Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51:4347–4354PubMedGoogle Scholar
  9. 9.
    Schmittgen TD, Wientjes MG, Badalament RA, Au JL-S (1991) Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res 51:3849–3856PubMedGoogle Scholar
  10. 10.
    Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL-S (1993) Penetration of mitomycin C in human bladder. Cancer Res 53:3314–3320PubMedGoogle Scholar
  11. 11.
    Wientjes MG, Badalament RA, Au JL-S (1993) Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C treatment for superficial bladder cancer. Cancer Chemother Pharmacol 32:255–262. doi:10.1007/BF00686169 PubMedCrossRefGoogle Scholar
  12. 12.
    Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ, International Mitomycin C Consortium (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93:597–604. doi:10.1093/jnci/93.8.597 PubMedCrossRefGoogle Scholar
  13. 13.
    Stephen RL, Miotti D, Bettoglio R, Rossi C, Bonezzi C (1994) Electromotive administration of a new morphine formulation: morphine citrate. Artif Organs 18:461–465. doi:10.1111/j.1525-1594.1994.tb02233.x PubMedCrossRefGoogle Scholar
  14. 14.
    Bellantone NH, Rim S, Francoeur ML, Rosadi B (1986) Enhanced percutaneous absorption via iontophoresis. Evaluation of an in vitro system and transport of model compounds. Int J Pharm 30:63–72. doi:10.1016/0378-5173(86)90136-5 CrossRefGoogle Scholar
  15. 15.
    Banga AK, Chien YW (1998) Iontophoretic delivery of drugs: fundamentals, developments and biomedical applications. J Control Release 7:1–24. doi:10.1016/0168-3659(88)90075-2 CrossRefGoogle Scholar
  16. 16.
    Prausnitz MR, Bose VG, Langer R, Weaver JC (1993) Electroporation of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 90:10504–10508. doi:10.1073/pnas.90.22.10504 PubMedCrossRefGoogle Scholar
  17. 17.
    Nightingale ER (1959) Phenomenological theory of ion solvation. Effective radii of hydrated ions. J Phys Chem 63:1381–1387. doi:10.1021/j150579a011 CrossRefGoogle Scholar
  18. 18.
    Di Stasi SM, Vespasiani G, Giannantoni A, Massoud R, Dolci S, Micali F (1997) Electromotive delivery of mitomycin C into human bladder wall. Cancer Res 57:875–880PubMedGoogle Scholar
  19. 19.
    Di Stasi SM, Giannantoni A, Massoud R, Dolci S, Navarra P, Vespasiani G, Stephen RL (1999) Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies. Cancer Res 59:4912–4918PubMedGoogle Scholar
  20. 20.
    Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high-risk superficial bladder cancer: a prospective randomized study. J Urol 170:777–782. doi:10.1097/01.ju.0000080568.91703.18 PubMedCrossRefGoogle Scholar
  21. 21.
    Brausi M, Campo B, Pizzocaro G, Rigatti P, Parma A, Mazza G, Vicini A, Stephen RL (1998) Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study. Urology 5:506–509. doi:10.1016/S0090-4295(97)00625-0 CrossRefGoogle Scholar
  22. 22.
    Riedl CR, Knoll M, Plas E, Pfluger H (1998) Intravesical electromotive drug administration technique: preliminary results and side effects. J Urol 159:1851–1856. doi:10.1016/S0022-5347(01)63174-4 PubMedCrossRefGoogle Scholar
  23. 23.
    Di Stasi SM, Storti L, Giurioli A, Zampa G, Liberati E, Sciarra M, Iorio B, Stephen RL (2008) Carcinoma in situ of the bladder: long-term results of a randomized prospective study comparing intravesical electromotive mitomycin-C, passive diffusion mitomycin-C and Bacillus Calmette-Guerin. Eur Urol Suppl 7(3):180 abs #439CrossRefGoogle Scholar
  24. 24.
    Sockett LJ, Borwell J, Symes A, Parker T, Montgomery BSI, Barber NJ (2008) Electro-motive drug administration (EMDA) of intravesical mitomycin-C in patients with high-risk non-invasive bladder cancer and failure of BCG immunotherapy. BJU Int 101(suppl 5):50 abs #U17Google Scholar
  25. 25.
    Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alfthan O (1995) Alternating mitomycin-C and Bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol 154:2050–2053. doi:10.1016/S0022-5347(01)66691-6 PubMedCrossRefGoogle Scholar
  26. 26.
    Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O (1996) Alternating mitomycin-C and Bacillus Calmette Guerin instillation prophylaxis for recurrent papillary (stages Ta–T1) superficial bladder cancer. J Urol 156:56–59. doi:10.1016/S0022-5347(01)65936-6 PubMedCrossRefGoogle Scholar
  27. 27.
    Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP (1998) Results of a randomised phase 3 trial of sequential intravesical therapy with mitomycin-C and Bacillus Calmette Guerin versus mitomycin-C alone in patients with superficial bladder cancer. J Urol 160:1668–1671. doi:10.1016/S0022-5347(01)62377-2 PubMedCrossRefGoogle Scholar
  28. 28.
    Kaasinen E, Wijkström H, Malmström PU, Hellsten S, Duchek M, Mestad O, Rintala E, Nordic Urothelial Cancer Group (2003) Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 43:637–645PubMedGoogle Scholar
  29. 29.
    Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, Stephen RL (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7:43–51. doi:10.1016/S1470-2045(05)70472-1 PubMedCrossRefGoogle Scholar
  30. 30.
    Di Stasi SM, Storti L, Giurioli A, Brausi M, Capelli G, Zampa G, Stephen RL (2008) Single immediate preoperative instillation of electromotive mintomycin-C plus trasurethral resection versus transurethral resection alone versus transurethral resection plus immediate mitomycin-C for pTa bladder tumors: long-term results of a prospective randomized trial. J Urol 179(suppl 4):585 abs #1707Google Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of Surgery/UrologyTor Vergata UniversityRomeItaly
  2. 2.Department of UrologyLandesklinikum ThermenregionBadenAustria

Personalised recommendations